IRB #

STUDY00022161

Title

[NCI CIRB] S1806: Phase III Randomized Trial of Concurrent Chemoradiotherapy with or without Atezolizumab in Localized Muscle Invasive Bladder Cancer

Principal Investigator

Jacqueline Vuky

Study Purpose

The purpose of this study is to compare the effects, good and/or bad, of chemotherapy and radiation therapy with or without the use of atezolizumab, which is used to treat bladder cancer. The combination of chemotherapy, radiation therapy and the immunotherapy atezolizumab is considered experimental.

Medical Condition(s)

Muscle Invasive Bladder Cancer
Localized Muscle Invasive Bladder Cancer
Invasive Bladder Cancer
Bladder Cancer

Eligibility Criteria

T2-T4a N0M0 urothelial carcinoma of the bladder.

Patients must be planning to receive one of the protocol specified chemotherapy regimens.

Patients must not have received any systemic chemotherapy for their bladder cancer.

Patients must not have had prior pelvic radiation.

Patients must not have received prior treatment for muscle invasive bladder cancer including neoadjuvant chemotherapy for the current tumor.

Age Range

18 - 99

Healthy Volunteers Needed

No

Duration of Participation

5 years from study entry

Minors Included

No

Contact

Knight Cancer Institute Clinical Trials
trials@ohsu.edu
503-494-1080

Sponsor

SWOG

Recruitment End

11/11/2022

Compensation Provided

No


Go Back